Published OnlineFirst October 6, 2010; DOI:[removed].CCR[removed]REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer Charles Comins, James Spicer, Andrew Protheroe, et

First Page		Document Content
Date: 2013-12-23 11:19:21 Reolysin Carbamates Organofluorides Oncolytics Biotech Oncolytic virus Docetaxel Head and neck cancer Gemcitabine Prostate cancer Medicine Viruses Cancer treatments		Published OnlineFirst October 6, 2010; DOI:[removed].CCR[removed]REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer Charles Comins, James Spicer, Andrew Protheroe, et Add to Reading List Source URL: www.oncolyticsbiotech.com Download Document from Source Website File Size: 402,12 KB Share Document on Facebook

	CABARET: Carboplatin and bevacizumab in recurrent glioblastoma study (Part 1) The CABARET trial is helping researchers answer an important health question. It is providing evidence for oncologists planning treatment for DocID: 1pDeC - View Document
	FINAL FOR DISTRIBUTION PSIOXUS THERAPEUTICS RAISES A £25M SERIES C INVESTMENT TO PROGRESS ONCOLYTIC VIRUS PLUS CHECKPOINT INHIBITOR COMBINATION STUDY IN METASTATIC COLORECTAL CANCER OXFORD, UK – 19 May 2015 – PsiOxu DocID: 19y3O - View Document
	Reolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer DocID: ZLVM - View Document
	This Week in Virology with Vincent Racaniello, Ph.D. Episode 131: A REOstat for cancer Hosts: Vincent Racaniello, Dickson Despommier, Alan Dove Guest: Brad Thompson, CEO of Oncolytics Biotech DocID: AFMv - View Document
	Published OnlineFirst November 24, 2010; DOI:[removed].CCR[removed]A Phase I Study of the Combination of Intravenous Reovirus Type 3 Dearing and Gemcitabine in Patients with Advanced Cancer Martijn P. Lolkema, H DocID: AuZz - View Document